JelloX Biotech, a leader in cancer pathology innovation, announces the opening of a new research lab in Phoenix, Arizona, to advance 3D imaging and AI technologies aimed at improving cancer diagnosis and treatment.
 |
| JelloX Biotech’s new research facility in Phoenix, Arizona, will leverage cutting-edge 3D pathology and AI technology to improve cancer detection and treatment, marking a major step in the fight against cancer. Image: JelloX |
Phoenix, Arizona, USA – April 15, 2025:
JelloX Biotech Inc., a Taiwan-based pioneer in cancer pathology, has announced the opening of its new research lab in the Discovery Oasis biotechnology hub in Phoenix, Arizona. The state-of-the-art facility is poised to advance the company’s groundbreaking work in 3D pathology and AI, with the aim of transforming cancer diagnosis and treatment.
The Discovery Oasis is a 120-acre development designed to foster collaboration among biotech companies, providing a space for cutting-edge research and innovation. JelloX’s lab will occupy 1,100 square feet, equipped with advanced technologies, including 3D imaging systems and AI tools, to enable more accurate and personalized cancer diagnoses.
Dr. Yen-Yin Lin, CEO of JelloX, emphasized the importance of collaboration in tackling complex medical issues like cancer: "Medical problems like cancer require many parties working together to create better treatments and patient care. We are excited to establish a research base in the U.S., where we can collaborate with other pioneering companies and contribute to the country’s leadership in biotech innovation."
At the heart of JelloX’s innovation is its 3D pathology technology, which offers significant advantages over traditional 2D tissue sampling methods. While conventional methods often provide limited information on tumors, 3D pathology can capture at least 50 times more data, offering a comprehensive view of a tumor’s biological structure. This higher sensitivity allows for earlier cancer detection, more precise treatment planning, and improved patient outcomes.
"3D pathology can identify cases that would have been missed by conventional methods, enabling earlier detection and treatment," Dr. Lin explained. "With 3D imaging, pathologists gain a deeper understanding of a tumor’s biology, which ultimately leads to more personalized and effective treatment options."
The technology has already shown promise in clinical research, particularly in cancers like colorectal cancer, esophageal cancer, and breast cancer (HER2 detection). JelloX’s collaborations with major healthcare institutions in Japan and Taiwan have highlighted the potential of 3D pathology to improve diagnostic accuracy and clinical outcomes across diverse patient populations.
JelloX’s 3D pathology technology also benefits a wide range of healthcare stakeholders. For physicians, the technology offers a more comprehensive data set and reduces workloads when integrated with AI. Pharmaceutical companies and research institutions can use the technology to enhance companion diagnostics (CDx) and support new drug development. Healthcare systems, in turn, can optimize medical resource allocation and reduce unnecessary costs.
Based in Hsinchu, Taiwan, JelloX Biotech is at the forefront of transforming cancer pathology through the integration of 3D imaging and AI. The new research lab in Phoenix marks a major milestone in the company’s mission to improve cancer diagnosis and treatment, positioning JelloX as a key player in the rapidly evolving field of precision oncology.